Phase III study to determine efficacy of durvalumab in stage II-III non-small cell lung cancer (NSCLC) after curative intent therapy. - MERMAID-2

Study identifier:D910MC00001

ClinicalTrials.gov identifier:NCT04642469

EudraCT identifier:2020-000612-30

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Medical condition

Carcinoma, non- small cell lung

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 30 Nov 2020
Primary Completion Date: 31 May 2023
Estimated Study Completion Date: 28 Feb 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria